Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 8:13 pm Purchase | 2026-03-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management, LLC | 13,860,028 9.900% | 1,167,641 (+9.20%) | Filing History |
| 2026-05-15 4:15 pm Purchase | 2026-03-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Trails Edge Capital Partners, LP | 8,057,345 6.100% | 1,912,147 (+31.12%) | Filing History |
| 2026-05-15 4:11 pm Purchase | 2026-03-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Commodore Capital LP | 14,054,940 9.900% | 7,247,433 (+106.46%) | Filing History |
| 2026-05-15 4:00 pm Sale | 2026-03-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | PERCEPTIVE ADVISORS LLC | 12,635,875 8.900% | -180,768 (-1.41%) | Filing History |
| 2026-02-17 6:22 pm Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management, LLC | 12,692,387 9.900% | 4,954,693 (+64.03%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Fairmount Funds Management LLC | 12,461,101 9.900% | 5,442,526 (+77.54%) | Filing History |
| 2026-02-17 4:00 pm Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | PERCEPTIVE ADVISORS LLC | 12,816,643 9.990% | 6,016,699 (+88.48%) | Filing History |
| 2026-02-13 5:04 pm Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Nantahala Capital Management, LLC | 7,037,916 5.680% | 1,739,292 (+32.83%) | Filing History |
| 2026-02-13 11:30 am Purchase | 2025-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Sands Capital Life Sciences Pulse Fund II, L.P. | 13,018,965 10.800% | 2,068,965 (+18.89%) | Filing History |
| 2025-12-31 5:00 pm Purchase | 2025-12-23 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Trails Edge Capital Partners, LP | 6,145,198 5.100% | 6,145,198 (New Position) | Filing History |
| 2025-08-14 8:27 pm Purchase | 2025-06-30 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management, LLC | 7,737,694 9.900% | 743,448 (+10.63%) | Filing History |
| 2025-08-13 11:17 am Unchanged | 2025-06-30 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Sands Capital Life Sciences Pulse Fund II, L.P. | 10,950,000 14.700% | 0 (Unchanged) | Filing History |
| 2025-02-14 9:04 pm Purchase | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | ADAR1 Capital Management, LLC | 6,994,246 9.990% | 6,994,246 (New Position) | Filing History |
| 2025-02-14 5:35 pm Purchase | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Armistice Capital, LLC | 3,529,006 4.990% | 2,770,121 (+365.03%) | Filing History |
| 2025-02-14 4:32 pm Purchase | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Nantahala Capital Management, LLC | 5,298,624 7.540% | 5,298,624 (New Position) | Filing History |
| 2025-02-14 4:08 pm Sale | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Point72 Asset Management, L.P. | 0 0.000% | -625,000 (Position Closed) | Filing History |
| 2025-02-14 3:45 pm Purchase | 2024-12-31 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Fairmount Funds Management LLC | 7,018,575 9.900% | 398,264 (+6.02%) | Filing History |
| 2024-11-14 3:31 pm Purchase | 2024-09-30 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Armistice Capital, LLC | 758,885 9.990% | 758,885 (New Position) | Filing History |
| 2024-10-28 5:26 pm Purchase | 2024-10-21 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | SP IKT Holdings LLC | 5,840,000 8.690% | 5,840,000 (New Position) | Filing History |
| 2024-10-28 4:00 pm Purchase | 2024-10-21 | 13G | INHIBIKASE THERAPEUTICS INC CO IKT | Soleus Private Equity Fund III, L.P. | 7,228,908 9.990% | 7,228,908 (New Position) | Filing History |